In patients with first-line metastatic triple-negative breast cancer who are not candidates for PD-1/PD-L1 inhibitors, ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, ...

Gilead Sciences’ randomised, global Phase III ASCENT-03 trial of Trodelvy (sacituzumab govitecan-hziy) has met its primary ...

After meeting the mark alongside Keytruda in PD-L1-positive breast cancer earlier this year, Gilead Sciences' antibody-drug ...

Gilead Sciences is well-positioned to continue to strengthen its position as a leader in the HIV therapy market. Learn more ...

Second Positive Phase 3 Trial in First-line Metastatic TNBC Where Trodelvy Has Demonstrated a Clinically Meaningful Benefit Versus Standard of Care Chemotherapy – – Trodelvy Has the Potential ...

Trodelvy (sacituzumab govitecan-hziy) is a brand-name IV infusion prescribed for certain types of breast cancer in adults. As with other drugs, Trodelvy can cause side effects, such as diarrhea ...

Trodelvy (sacituzumab govitecan-hziy) is a prescription drug used to treat certain kinds of breast cancer. This drug can interact with some other medications. For example, Trodelvy can interact ...

Gilead Sciences, Inc. GILD announced positive top-line results from yet another late-stage study on breast cancer drug, Trodelvy (sacituzumab govitecan-hziy). Data from the phase III ASCENT-03 ...

ASCENT-03: Trodelvy® Demonstrates Highly Statistically Significant & Clinically Meaningful Improvement in Progression Free Survival in Patients With First-line Metastatic Triple-Negative Breast ...